Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors
- 22 January 2007
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 117 (1), 20-27
- https://doi.org/10.1016/j.jconrel.2006.10.007
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Regulation of Multidrug Resistance by Pro-Inflammatory CytokinesCurrent Cancer Drug Targets, 2006
- Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumorJournal of Controlled Release, 2005
- Weekly administration of paclitaxel: theoretical and clinical basisCritical Reviews in Oncology/Hematology, 2002
- Role of weekly paclitaxel in the treatment of advanced ovarian cancerCritical Reviews in Oncology/Hematology, 2002
- Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic DiseaseThe Oncologist, 2002
- Multidrug Resistance Gene-1 Is a Useful Predictor of Paclitaxel-Based Chemotherapy for Patients with Ovarian CancerGynecologic Oncology, 2002
- Cancer chemoresistance: The relationship between p53 and multidrug transportersInternational Journal of Cancer, 2002
- Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian CancerJournal of Clinical Oncology, 2001
- Multidrug resistance-associated protein: A protein distinct from P-glycoprotein involved in cytotoxic drug expulsionGeneral Pharmacology: The Vascular System, 1997
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1976